

**Publications** - (Listed in alphabetical order according to the first appearance of the ID faculty's name)

1. **Beckwith CG**, Larney S, **Flanigan TP**. HCV Testing and Drug Use in North America; Is There More Than Meets the Eye? *Clin Infect Dis* 2014; 58(6):762-4. PMID: 2436330  
PMCID: PMC3935502
2. Larney S, Kopinski H, **Beckwith CG**, Zaller ND, Jarlais DD, Hagan H, **Rich JD**, Vandenberg BJ, Degenhardt. The incidence and prevalence of hepatitis C in prisoners and other closed settings: Results of a systematic review and meta-analysis. *Hepatology* 58:1215-24, 2013. PMCID: PMC3723697
3. **Beckwith CG**, Bazerman L, Gillani F, Tran L, Larson B, Rivard S, **Flanigan T**, **Rich J**. The Feasibility of Implementing the HIV Seek, Test, and Treat Strategy in Jails. *AIDS Patient Care STDS* 2014;28(4):183-7. PMID: 24617960 PMCID: PMC3985510
4. Larney S, **Beckwith C**, Zaller N, **Montague B**, **Rich JD**. Seek, test, treat and retain for hepatitis C in the United States criminal justice system. *Int J prisoner health* (accepted for publication March, 2014). NIHMSID: 580136 (in process)
5. **Beckwith CG**, Kurth A, Bazerman L, Solomon L, Patry E, Rich JD, Kuo I. HCV Testing in Criminal Justice Facilities: A Routine Testing Recommendation is Urgently Needed. *American Journal of Public Health*, Accepted for publication. April, 21 2014.
6. Kosgei R, Szkwarko D, Callens S, Gichangi P, Temmerman M, Kihara AB, Sitienei J, Cheserem E, Ndavi P, Ried T, **Carter EJ**. Screening for tuberculosis in pregnancy: Do we need more than symptom screen? A case from western Kenya. Accepted *Public Health Action* 2013; 3(4): 294-298.
7. Naureckas C, **Carter EJ**, Gardner A. HIV Testing in U.S. Tuberculosis Care Settings: A Survey of Current Practice and Perceived Barriers. *J Public Health Management Practice* 2013 00(00) 1-5.
8. Klasen E, Miranda J, Khattry S, Menya D, Gilman R, Tielsch J, Kennedy C, Dreibeldis R, Naithani N, Kimaiyo S, Chiang M, **Carter EJ**, Sherman CB, Breyse P, Checkley W. Feasibility Intervention Trial of two types of improved cookstoves in three resource limited settings: study protocol for a randomized controlled trial. *Trials* 2013, 14: 327  
doi:10.1186/1745-6215-14-327.
9. Creswell J, Codlin A, Andre E, Micek M, Bedru A, **Carter EJ**, Yadrav R, Mosneaga A, Rai B, Banu S, Brouwer M, Blok L, Sahu S, Ditiu L. Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. *BMC Infectious Disease* 2014,14.2. <http://www.biomedcentral.com/1471-2334/14/2>
10. Lagat D, Delong A, Wellnius G, **Carter EJ**, Bloomfield G, Velasquez E, Hogan J, Kimaiyo S, Sherman C. Risk Associated with Isolated Right Heart Failure (IRHF) in women in western Kenya: a Pilot Study. *Global Heart* 9:(2014), pp. 249-254.

11. Baliff M, Nhandu, wood R, Dusingize JC, **Carter EJ**, Cortes CP, McGowna CC, Diero L, Graber C, Renner L, Wawerlander D, Kiertiburanakul S, Du QT, Sterling TR, Eggger M, Fenner L. Detection and management of drug resistant tuberculosis in HIV-infected patients in lower-income countries. *Int J Tuberc Lung Dis* <http://dx.doi.org/10.5588/ijtld.14.0106>
12. Echenique IA, **Chan PA**, Chapin KC, Andrea SB, Fava JL, **Mermel LA**. Clinical characteristics and outcomes in hospitalized patients with respiratory viral co-infection during the 2009 H1N1 influenza pandemic. *PLOS ONE* 8(4): e60845, 2013.
13. Sison N, Yolken A, Poceta J, Mena L, **Chan PA**, Barnes A, Smith E, Nunn A. Healthcare Provider Attitudes, Practices, and Recommendations for Enhancing Routine HIV Testing and Linkage to Care in the Mississippi Delta Region. *AIDS Patient Care STDs* 2013;27(9):511-7.
14. Grin B, **Chan PA**, Operario D. Knowledge of Acute HIV Infection Among Gay and Bisexual Male College Students. *The Journal of American College Health* 2013;61(4):232-41.
15. **Chan PA**, MB Reitsma, A DeLong, B Boucek, A Nunn, M Salemi, **R Kantor**. Phylogenetic and Geospatial Evaluation of HIV-1 Subtype Diversity at the Largest HIV Center in Rhode Island. *Infection Genetics and Evolution* 2014 (Epub ahead of print). PMID: 24721515.
16. **Chan PA**, Huang A, DeLong AK, **Hogan JW**, Salemi M, Mayer KH, Operario D, **Kantor R**. Molecular phylogenetic investigation of local HIV transmission reveals complex network dynamics among men who have sex with men. 2014, In process.
17. **Chan PA**, Maher J, Poole D, **Alexander-Scott N**, R. Ducharme B, Yates G, Benben S, Nunn A, Comella J, Bandy U, **Montague BT**, **Kojic E**, Chapin K, **Flanigan TP**. Addressing the Increasing Burden of Sexually Transmitted Infections in Rhode Island. *RI Med J*, publication pending 2014.
18. Nunn A, Maccarthy S, Barnett N, Rose J, **Chan PA**, Yolken A, Cornwall A, Chamberlain N, Barnes A, Riggins R, Moore E, Simmons D, Parker S, Mena L. Prevalence and Predictors of Concurrent Sexual Partnerships in a Predominantly African American Population in Jackson, Mississippi. *AIDS and Behavior* 2014 (Epub ahead of print).
19. **Cunha CB**, Opal SM: Middle East Respiratory Syndrome (MERS): A New Zoonotic Viral Pneumonia. *Virulence* 5:650-4, 2014.
20. **Cunha CB**. Infectious Disease Differential Diagnosis. In: Cunha BA (ed.): *Antibiotic Essentials* (12<sup>th</sup> Edition). Jones & Bartlett. Sudbury, Massachusetts, 2013.
21. Cunha BA, Hage JE, Schoch PE, **Cunha CB**, Bottone EJ, Torres DC. Overview of Antimicrobial Therapy. In: Cunha, B.A. (ed.): *Antibiotic Essentials* (12<sup>th</sup> Edition). Jones & Bartlett. Sudbury, Massachusetts, 2013.
22. Cunha BA, Bruschi JL, Nichols RL, Papanicolaou G, Hage JE, Koff RS, Rex JH, Cleri DJ, **Cunha CB**, Fischer SA, Schlossberg D. Empiric Therapy Based on Clinical Syndrome. In:

Cunha BA (ed.): *Antibiotic Essentials* (12<sup>th</sup> Edition). Jones & Bartlett. Sudbury, Massachusetts, 2013.

23. **Reece RM, Cunha CB, Rich JD.** *Corynebacterium minutissimum* vascular graft infection: case report and review of 281 cases of prosthetic device related corynebacteria infections. *Scand J Infect Dis* (accepted for publication April, 2014) PMID: 24934988
24. Khozaim K, Orang'o E, Christoffersen-Deb A, Itsura P, Oguda J, Muliro H, Ndiema J, Mwangi G, Strother M, **Cu-Uvin S**, Rosen B, Washington S. Successes and challenges of establishing a cervical cancer screening and treatment program in western Kenya. *Int J Gynaecol Obstet* (2014);124(1):12-18. PMID: 24140218
25. Venkatesh KK, **Cu-Uvin S.** Anatomic and Hormonal changes in the Female Reproductive Tract Immune Environment during the Life Cycle: Implications from HIV/STI prevention research. *Am J Reprod Immunol.* 2014; 71(6):495-504. PMID: 24832617
26. Sudenga SL, Wiener HW, King CC, Rompalo AM, **Cu-Uvin S**, Klein RS, Shah KV, Sobel JD, Jamieson DJ, Shrestha S. Dense Genotyping of Immune-related Loci Identifies variants associated with Clearance of HPV among HIV-positive women in the HIV Epidemiology Research Study (HERS). *PLoS One.* 2014; 9(6):e99109. PMID: 24918582
27. Mitchell SL, Shaffer ML, Loeb MB, Givens JL, Habtemariam D, Kiely DK, **D'Agata E.** Infection management and multidrug-resistant organisms in nursing home residents with advanced dementia. *JAMA Intern Med.* 2014 Oct 1;174(10):1660-7. PMID: 25133863
28. Drolet, BC, Khokhar MT, **Fischer SA.** The 2011 Duty-Hour Requirements- A Survey of Residency Program Directors. *N Engl J Med.* 2013;368(8):694-697.
29. Drolet BC, Whittle SB, Khokhar MT, **Fischer SA**, Pallant A. Approval and perceived impact of duty hour regulations: a survey of pediatric program directors. *Pediatrics* 2013;132:819024.
30. Christino, M, Matson AP, **Fischer SA**, Reinert SE, DiGiovanni CW, Fadale PD. Paperwork Versus Patient Care: A Nationwide Survey of Residents' Perceptions of Clinical Documentation Requirements and Patient Care. *J Grad Med Ed.* 2013;600-604.
31. Drolet, BC, Anandarajah G, **Fischer, SA.** The Impact of 2011 Duty Hours Requirements on Family Medicine Residents. *Family Medicine* 2014;46(3):215-8.
32. Bariteau, JT, Born, CT, Hayda, RA, McDonnell, M, Waryasz, GR, **Fischer, SA.** Fungal Osteomyelitis and Septic Arthritis, *Journal of the American Academy of Orthopedic Surgeons.* June 2014; 22(6): 390-401.
33. Daniels, A, DePasse, J, **Fischer, SA.** The Current State of US Spine Surgery Training: a Survey of Residency and Spine Fellowship Program Directors, *Spine Deformity: The Official Journal of the Scoliosis Research Society.* May 2014; 2(3): 176-185.

34. **Fischer SA.** Infections in the Immunocompromised Host. In *Andreoli and Carpenter's Cecil Essentials of Medicine* ed. 2014. In Press
35. Chitsaz E, Mayer JP, Krishnan A, Springer SA, Marcus R, Zaller N, Jordan AO, Lincoln T, **Flanigan TP**, Porterfield J, Altice FL. Contribution of Substance Use Disorders on HIV Treatment Outcomes and Antiretroviral Medication Adherence among HIV-infected Persons Entering Jail. *AIDS Behav* 2013 Oct;17 Suppl 2:S118-27. PMID: 23673792 PMCID: PMC3818019
36. **Flanigan TP.** Jails: The New Frontier: HIV Testing, Treatment and Linkage to Care after Release. *AIDS Behav* 2013 Oct;17 Suppl 2:S83-5. PMID: 23975472 PMCID: PMC3876465
37. Costello JF, Sliney A, MacLeod C, Carpentier M, Garofalo R, **Flanigan T.** Implementation of routine HIV testing in an acute care hospital in Rhode Island: A Nurse-initiated opt-out pilot project. *J Assoc Nurses AIDS Care* 2013;24(5):460-8. Epub 2012 Dec 25. PMID: 23270811
38. Larney S, Mahowald MK, Scharff N, **Flanigan TP, Beckwith CG,** Zaller ND. Epidemiology of hepatitis C virus in Pennsylvania state prisons, 2004-2012: Limitations of 1945-1065 birth cohort screening in correctional settings. *Am J Public Health* 2014;104(6):e69-74. PMID: 24825235
39. Reece R, Dugdale C, Touzard-Romo F, Noska A, **Flanigan T,** **Rich JD.** Care at the crossroads: navigating the HIV, HCV, and substance abuse syndemic. *Fed Pract* (accepted for publication January, 2014). NIHMSID: 616554 (in process)
40. Chibebe J, Sabino CP, Tan X., Junqueira JC, Wang Y, **Fuchs BB,** Jorge A, Tegos GT, Hamblin MR, **Mylonakis E.** Selective photoinactivation of *Candida albicans* in the non-vertebrate host infection model *Galleria mellonella*. *BMC Microbiology* 2013;13(1):217.
41. Arvanitis M, **Fuchs BB, Mylonakis E.** Nonmammalian model systems to investigate fungal biofilms. *Methods Mol Biol* 2014;1147:159-72.
42. Borghi E, Romagnoli S, **Fuchs BB,** Cirasola D, Perdoni F, Tosi D, Braidotti P, Bulfamante G, Morace G, **Mylonakis E.** Correlation between *Candida albicans* biofilm formation and invasion of the invertebrate host *Galleria mellonella*. *Future Microbiol* 2014;9:163-73.
43. Rajamuthiah R, **Fuchs BB,** Jayamani E, Kim Y, Larkins-Ford J, Conery A, Ausubel FM, **Mylonakis E.** Whole animal automated platform for drug discovery against multi-drug resistant *Staphylococcus aureus*. *PLoS ONE* 2014;9(2):e89189.
44. Desalermos A, Tan X, Rajamuthiah R, Arvanitis M, Wang Y, Li D, Kourkoumpetis TK, **Fuchs BB, Mylonakis E.** A Multi-host approach for the systemic analysis of virulence factors in *Cryptococcus neoformans*. *J Infect Dis* 2014;(accepted)
45. Arvanitis M, Anagnostou T, **Fuchs BB,** Caliendo AM, **Mylonakis E.** Molecular and nonmolecular diagnostic methods for invasive fungal infections. *Clin Microbiol Rev* 2014;(2):490-526.

46. Tan X, **Fuchs BB**, Wang Y, Chen W, Yuen GJ, Chen RB, Jayamani E, Anastassopoulou C, Pukkila-Worley R, Coleman JJ, **Mylonakis E**. The role of *Candida albicans* SPT20 in filamentation, biofilm formation, and pathogenesis. *PLoS One* 2014; 9(4):e94468.
47. T Liu, **JW Hogan**, L Wang, S Zhang, **R Kantor**. Optimal allocation of gold standard testing under constrained availability: application to assessment of HIV treatment failure. *Journal of the American Statistics Association* 2013;108:1173-88. PMC3963362.
48. M Mann, L Diero, E Kemboi, F Mambo, W Injera, A DeLong, L Schreier, K Wools Kaloustian, N Buziba, **R Kantor**. Unplanned Antiretroviral Treatment Interruptions Induced by the Kenyan Post-Election Crisis are Associated with HIV virologic Failure. *Journal of AIDS* 2013;64:220-224. PMC3920989.
49. M Mann, MN Lurie, S Kimaiyo, **R Kantor**. Effects of Political Conflict Induced Treatment Interruptions on HIV Drug Resistance. *AIDS Reviews* 2013;15:15-24, 2013. PMID 23449225.
50. **Kantor R**. Research Components of the Brown Kenya Program: A Personal and Professional Perspective. *RI Medical Journal* 2013;96:16-19. PMID 24087816.
51. **Kantor R**, D Bettendorf, M Mann, RJ Bosch, D Katzenstein, **S Cu-Uvin**, R D'Aquila, L Frenkel, A Erice, S Fiscus, R Coombs for the ACTG A5077 Study Team. HIV-1 RNA Levels and Antiretroviral Drug Resistance in Blood and Non-Blood Compartments Differ for HIV-1–Infected Men and Women. *PLOS One* 2014;9:393537. PMC3974754.
52. P Phanuphak, S Sirivichayakul, A Jiamsakul, S Sungkanuparph, N Kumarasamy, MP Lee, **R Kantor**, on behalf of the TASER-M Cohort. Transmitted Drug Resistance and Antiretroviral Treatment Outcomes in Non- Subtype B HIV1- Infected Patients in South East Asia. *Journal of AIDS* 2014;66:74-79. PMC4074771.
53. G Alemnji, P Fonjungo, T Peter, **R Kantor**, R Albalak, J Nkengasong. The Centrality of Laboratory Services in the Continuum of HIV Treatment and Prevention Cascade: need for effective linkages and referrals. *AIDS Patient Care and STDs* 2014;28:268-273. PMID 24742299.
54. A Jiamsakul, S Sungkanuparph, M Law, **R Kantor**, J Praparattanapan, PCK Li, P Phanuphak, T Merati, W Ratanasuwan, C KC Lee, R Ditangco, M Mustafa, T Singtoroj, S Kiertiburanakul. HIV Multi-Drug Resistance at First-line Antiretroviral Failure and Subsequent Virological Response in Asia. *Journal of the International AIDS Society* 2014;17:19053. PMC4139921.
55. **Knoll BM**, Pharmacokinetics of oral isavuconazole in a patient after Roux-en-Y gastric bypass surgery. *J Antimicrob Chemother* 2014 Aug 11. [Epub ahead of print]
56. **Knoll BM**. Update on nontuberculous mycobacterial infections in solid organ and hematopoietic stem cell transplant recipients. *Curr Infect Dis Rep* 2014;16(9):421.
57. **Knoll BM**, Lindesmith LC, Yount BL, Baric RS, Marty FM. Resolution of Diarrhea in an Immunocompromised Patient with Chronic Norovirus Gastroenteritis Correlates with

Constitution of Specific Antibody Blockade Titer. *Austin Journal of Clinical Medicine* 2014;1 (1)

58. **Knoll BM, Mylonakis E.** Antibacterial bioagents based on principles of bacteriophage biology: an overview. *Clin Infect Dis* 2014 Feb;58(4):528-34.
59. Kearny A, **Knoll BM.** Myopericarditis associated with *Fusobacterium nucleatum* caused liver abscess. *Scand J Infect Dis* 2014 [accepted for publication]
60. Mahmood A, Chaump M, **Knoll B,** Aswad B. Pulmonary zygomycosis in a diabetic patient: treated with pneumonectomy and antifungal agents. *R I Med J* (2013). 2014 Sep 2;97(9):44-5.
61. Varatharaj P, **Knoll B,** Baddour L, Wilson W. Prosthetic valve endocarditis. Principles and Practice of Infectious Diseases 8th ed. Mandell, Douglas & Bennett, Elsevier/Churchill, USA 2014; Chapter 83.
62. Baker JV, Hullsiek KH, Singh A, Wilson E, Henry K, Lichtenstein K, Onen N, **Kojic E,** Patel P, Brooks JT, Hodis HN, Budoff M, Sereti I, for the CDC SUN Study Investigators. Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort. *AIDS* 2014; 28(6):831-40, PMID:24370480.
63. Morrow KM, Fava JL, Rosen RK, Vargas S, Shaw JG, **Kojic EM,** Kiser PF, Friend DR, Katz D. Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: Relating user perceptions and experiences to formulation properties. *AIDS Res Hum Retroviruses* 2014; (1):78-91, PMID:24180360.
64. Baker JV, Hullsiek KH, Singh A, Wilson E, Henry K, Lichtenstein K, Onen N, **Kojic E,** Patel P, Brooks JT, Hodis HN, Budoff M, Sereti I; CDC Sun Study Investigators. Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort. *AIDS* 2014; 28(6):831-40, PMID:24370480.
65. **Kojic EM,** Kang M, Cespedes MS, Umbleja T, Godfrey C, Allen RT, Firnhaber C, Grinsztejn B, Palefsky JM, Webster-Cyriaque JY, Saah A, Aberg JA, **Cu-Uvin S.** Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1 infected women. *Clin Infect Dis* 2014; 59(1):127-35, PMID:24723284.
66. Wilson EM, Singh A, Hullsiek KH, Gibson D, Henry WK, Lichtenstein K, Onen NF, **Kojic E,** Patel P, Brooks JT, Sereti I, Baker JV, CDC SUN study investigators. Monocyte activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection. *J Infect Dis* 2014; [Epub ahead of print] PMID:24813472.
67. Dugdale C, Chow B, Yakirevich E, **Kojic E, Knoll B.** Prolonged pyrexia and hepatitis: Q fever. *Am J Med* 2014; Jun 11 [Epub ahead of print] PMID:24929020.
68. **Kwara A,** Cao L, Yang H, Poethke P, Kurpewski J, **Tashima KT,** Mahjoub BD, Court MH, Peloquin CA. Factors associated with variability in rifampin plasma pharmacokinetics and

the relationship between rifampin concentrations and induction of efavirenz clearance. *Pharmacotherapy* 2014; 34:265-71.

69. Haas DW, **Kwara A**, Richardson DM, Baker P, Papageorgiou I, Acosta EP, Morse GD, Court MH. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. *J Antimicrob Chemother* 2014;69:2175-82.
70. Court MH, Almutairi F, Greenblatt D, Hazarika S, Sheng H, Klein K, Zanger U, Bourgea J, Patten C, **Kwara A**. Isoniazid mediates the *CYP2B6*\*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6. *Antimicrob Agents Chemother* 2014;58:4145-4152.
71. Hosek, S, Siberry G, Bell M, **Lally M**, et al. Project PrEPare (ATN082): The Acceptability and Feasibility of an HIV Pre-Exposure Prophylaxis (PrEP) Trial with Young Men who Have Sex with Men (YMSM). *J of Acquired Immune Deficiency Syndromes* 62(4):447-56, 2013. PMC3656981
72. Ott MA, Alexander AB, **Lally M**, Steever JB, Zimet GD, and the Adolescent Trials Network for HIV/AIDS Interventions. Preventive Misconception and Adolescents' Knowledge about HIV Vaccine Trials. *Journal of Medical Ethics* 39(12):765-71, 2013. PMC3677956
73. Hosek, SG, Green KR, Siberry G, **Lally M**, et al, and The Adolescent Medicine Trials Network for HIV/AIDS Interventions. Integrating Behavioral HIV Interventions into Biomedical Prevention Trials with Youth: Lessons from Chicago's Project PrEPare. *Journal of HIV/AIDS & Social Services*, 12(3-4):333-348, 2013. PMC3818104
74. **Lally M**, Goldsworthy R, Sarr M, Kahn J, Brown L, Peralta L, Zimet G. Evaluation of an Intervention Among Adolescents to Reduce Preventive Misconception in HIV Vaccine Clinical Trials. *Journal of Adolescent Health* 55(2):254-9, 2014. PMC4108563
75. Tang, X., Zheng, D., Hu, P., Zeng, Z., **Li, M.**, Tucker, L., Monahan, R., Resnick, M.B., Liu, M. and **Ramratnam, B.** (2014) Glycogen Synthase Kinase 3 beta (GSK3-beta) inhibits microRNA-183/96/182 cluster via beta-Catenin/TCF/LEF1 pathway in gastric cancer cells. *Nucleic Acids Research* 42(5):2988-98. Epub 2013 Dec 13 PMID:24335145
76. **Li, M. and Ramratnam, B.** Proteomic characterization of exosomes from HIV-1 infected cells. *HIV Protocols (Methods in Molecular Biology)* In press
77. **Mermel LA**, Jefferson J, Blanchard K, Parenteau S, Mathis B, Chapin K, Machan JT. Reducing Clostridium difficile incidence, colectomies, and crude mortality in the hospital setting: a successful multi-disciplinary approach. *Jt Comm J Qual Patient Saf* 39:398-405, 2013.
78. Angione SL, Sarma AA, Novikov A, Fieber J, Seward L, **Mermel LA**, Tripathi A. A novel subtyping assay for detection of Clostridium difficile virulence genes. *J Mol Diagn* 16:244-252, 2014.

79. Kassakian SZ, **Mermel LA**. Changing epidemiology of infections due to extended spectrum beta-lactamase producing bacteria. *Antimicrob Resist Infect Control* 3:9DOI: 10.1186/2047-2994-3-9, 2014.
80. **Mermel LA**, Bert A, Chapin KC, McVeigh L. Intraoperative stopcock and manifold colonization of newly inserted peripheral intravenous catheters. *Infect Control Hosp Epidemiol*, Published online Jul 23, 2014. <http://www.jstor.org/stable/10.1086/677626>.
81. Luther M, **Mermel LA**, LaPlante, K. Comparison of a free fatty acid (ML8-X10 oil in water micro emulsion), taurolidine-citrate-heparin, and vancomycin-heparin antimicrobial lock solutions in the eradication of biofilm-producing staphylococci from central venous catheters. *J Antimicrob Chemother Advance Access* published August 4, 2014; doi:10.1093/jac/dku281.
82. **Mermel LA**. What is the evidence for intraluminal colonization of hemodialysis catheters? *Kidney Int* 2014 86: 28-33.
83. Yokoe DS, Anderson DJ, Berenholtz SM, Calfee DP, Dubberke ER, Ellingson K, Gerding DN, Haas J, Kaye KS, Klompas M, Lo E, Marschall J, **Mermel LA**, Nicolle L, Salgado C, Bryant K, Classen D, Crist K, Foster N, Humphreys E, Padberg J, Podgorny K, Vanamringe M, Weaver T, Wise R, Maragakis LL. Introduction to "a compendium of strategies to prevent healthcare-associated infections in acute care hospitals: 2014 updates". *Infect Control Hosp Epidemiol* 35:455-459, 2014.
84. **Mermel LA**, Alang, N. Adverse Effects Associated with Ethanol Catheter Lock Solutions: A Systematic Review. *J Antimicrob Chemother* on line ahead of print June 2, 2014; doi:10.1093/jac/dku182.
85. Marschall J, **Mermel LA**, Fakih M, Hadaway L, Kallen A, O'Grady NP, Pettis AM, Rupp ME, Sandora T, Maragakis LL, Yokoe DS. Strategies to prevent central line-associated bloodstream infections in acute care hospitals: 2014 update. *Infect Control Hosp Epidemiol* 35:753-771, 2014.
86. Safdar N, Maki DG, **Mermel LA**. Infections due to infusion therapy. In: Jarvis W, ed. Bennett and Brachman's Hospital Infections (6th ed), Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, 2014, pp 561-592.
87. **Montague B, Rana R, Wing EJ, Flanigan T**: Chapter 101. Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome. In Benjamin IJ, Griggs RC, Wing EJ, Fitz G (Eds). Andreoli and Carpenter's Cecil Essentials of Medicine. Elsevier, Inc., 2014. 9<sup>th</sup> edition. (in press)
88. Lee JY, Reece R, **Montague B, Rana A, Alexander-Scott N, Flanigan T**. The Future of Generic HIV Drugs in Rhode Island. *RI Med J* 96(9):30-3, 2013.
89. Solomon L, **Montague BT, Beckwith CG**, Baillargeon J, Costa M, Dumont D, Kuo I, Kurth A, **Rich JD**. Survey finds that many prisons and jails have room to improve HIV testing and coordination of post release treatment. *Health Aff* 33(3):434-42, 2014. PMID:

90. **Montague BT**, Kahler C, Colby S, McHugh K, Squires D, Fitzgerald B, Operario D, Gallagher D, Monti P, Mayer K. Attitudes and training needs of New England HIV care and addiction treatment providers: opportunities for better integration of HIV and alcohol treatment services. *Addictive Disorders and their treatment* (epub ahead of print November 13, 2013).
91. **Montague BT, Alexander-Scott N**, Bandy U, Comella J, **Kwara A**. Tuberculosis Control in RI: Maintaining Control Efforts in the Context of Declining Incidence and Funding for Tuberculosis Control. *RI Med J*, publication pending 2014.
92. Umoren R, **Montague BT**, Musa N. Global Health Partnership Building and Collaboration. (chapter) *Developing Global Health Programming: A Guidebook for Medical and Professional Schools*, 2<sup>nd</sup> ed. Global Health Collaborations Press 2014.
93. Li DD, Xu Y, Zhang D, Quan H, **Mylonakis E**, Hu DD, Li MB, Zhao LX, Zhu LH, Wang Y, Jiang YY. Fluconazole assists berberine to kill fluconazole-resistant *Candida albicans*. *Antimicrob Agents Chemother* 2013;57(12):6016-27. PMID: 24060867
94. Muhammed M, Anagnostou T, Desalermos A, Kourkoumpetis T, Carneiro H, Glavis-Bloom J, Coleman JJ, **Mylonakis E**. Fusarium infection: Report of 26 cases and review of 97 cases from the literature. *Medicine* (Baltimore). 2013;92(6):305-16. PMID: 24145697
95. Anagnostou T, Arvantis M, Kourkoumpetis T, Desalermos A, Carneiro H, **Mylonakis E**. Nocardiosis of the central nervous system: Experience from a general hospital and review of 84 cases. *Medicine* (Baltimore). 2014;93(1):19-32. PMID: 24378740
96. Kourbeti IS, **Mylonakis E**. Fungal central nervous system infections: prevalence and diagnosis. *Expert Rev Anti Infect Ther* 2014;12(2):265-73.
97. Li DD, Zhao LX, **Mylonakis E**, Hu GH, Zou Y, Huang TK, Yan L, Wang Y, Jiang YY. In vitro and in vivo activity of pterostilbene against *Candida albicans* biofilms. *Antimicrob Agents Chemother* 2014;58(4):2344-55. PMID: 24514088
98. Chen R, Li X, Lu S, Ma T, Huang X, **Mylonakis E**, Liang Y, Xi L. Role of extracellular signal-regulated kinases 1 and 2 and p38 mitogen-activated protein kinase pathways in regulating replication of *Penicillium marneffeii* in human macrophages. *Microbes Infect* 2014;16(5):401-8.
99. Huang X, Li D, Xi L, **Mylonakis E**. *Caenorhabditis elegans*: A Simple Nematode Infection Model for *Penicillium marneffeii*. *PLoS One*. 2014;9(9):e108764.
100. Luther MK, Arvanitis M, **Mylonakis E**, LaPlante KL. Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming *Enterococcus faecalis* or *E. faecium* in an in vitro pharmacodynamic model using simulated endocardial vegetations

and an in vivo survival assay using *Galleria mellonella* larvae. *Antimicrob Agents Chemother* 2014;58(8):4612-20.

101. Dolla NK, Chen C, Larkins-Ford J, Rajamuthiah R, Jagadeesan S, Conery AL, Ausubel FM, **Mylonakis E**, Bremner JB, Lewis K, Kelso MJ. On the mechanism of berberine-INF55 (5-Nitro-2-Phenylindole) hybrid antibacterials. *Aust J. Chem.* (in press).
102. Rajamuthiah R, **Mylonakis E**. Effector triggered immunity activation of innate immunity in metazoans by bacterial effectors. *Virulence* (in press).
103. Jayamani E, **Mylonakis E**. Effector triggered manipulation of host immune response elicited by different pathotypes of *Escherichia coli*. *Virulence* (in press).
104. Zervou FN, Zacharioudakis IM, **Mylonakis E**. *Ann Intern Med.* 2014 Oct 21;161(8):JC9. doi: 10.7326/0003-4819-161-8-201410210-02009. No abstract available. PMID: 25329226
105. Kling HM, **Nau GJ**, Ross TM, Evans TG, Chakraborty K, Empey KM, Flynn JL. Challenges and future in vaccines, drug development, and immunomodulatory therapy. *Ann Am Thorac Soc.* 2014 Aug;11 Suppl 4:S201-10. PMID: 25148426 [PubMed - in process]
106. Khan S, Sallum UW, Zheng X, **Nau GJ**, Hasan T. Rapid optical determination of  $\beta$ -lactamase and antibiotic activity. *BMC Microbiol.* 2014;14:84. PMID: 24708478 [PubMed - in process]
107. Brown MJ, Russo BC, O'Dee DM, Schmitt DM, **Nau GJ**. The contribution of the glycine cleavage system to the pathogenesis of *Francisella tularensis*. *Microbes Infect.* 2014;16(4):300-9. PMID: 24374051 [PubMed - in process]
108. **Opal SM**, Laterre P-F, Francois B, LaRosa SP, Angus DC, Mira J-P, Wittebole X, Dugenier T, Parrotin D, Tidswell M, Tillis T, Jaurequi A, Krell E, Pachel Y, Takahashi H, Peckelsen A, Cordasco D, Chang C, Oeye E, Aikawa N, Maruyama T, Schein R, Kalil A, Van Nuffelen M, Lynn M, Rossignol D, Gogate J, Roberts M, Wheeler J, Vincent J-L, and the ACCESS Study Group: Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized study. *Journal of the American Medical Association* 2013;309(11): 1154-1162.
109. Artenstein A, Higgins T, **Opal SM**. Sepsis and scientific revolutions. *Critical Care Med* 2013; 41(12): 2770-2772.
110. Wang J, Tai W, Angione S, John A, **Opal SM**, Artenstein A, Tripathi A. Subtyping Clinical Isolates of Influenza A Virus using a Simple Method to Amplify RNA Targets (SMART). *Journal of Clinical Microbiology* 2013;51(10):3324-3320.

111. Wittebole X, DeRooocke S, **Opal SM**. Bacteriophage therapy as a novel treatment for multidrug resistant pathogens. *Virulence* 2013; 4 (8): 1-10.
112. Angione S, Inde Z, Beck C, Artenstein A, **Opal SM**, Tripathi A. Microdroplet sandwich real-time RT-PCR for detection of pandemic and seasonal influenza subtypes. *PLoS ONE* 2013;8(9)13: e73497
113. **Opal SM**, Dellinger RP, Vincent JL, Angus D, Masur H. The next generation of sepsis trials: a critical reassessment after the demise of human recombinant activated protein C. *Critical Care Medicine* 2014; 42(7): 1714-1721.
114. LaRosa S, **Opal SM**. Sepsis and septic shock. *Scientific American Medicine. Infectious Disease*. Scientific American Medicine 2014; 37(7): DOI:10.23/7900.1147
115. Bulger EM, Maier RV, Sperry J, Joshi M, Henry S, Moore FA, Moldower LL, Demetriades D, Talvig P, Schreiber M, Ham B, Cohen M, **Opal SM**, Segalovich I, Maislin G, Hoffman Y, Shirvan A. A Novel Drug for Treatment of Necrotizing Soft Tissue Infections: Results of a Phase 2a Randomized Controlled Trial of AB103, a CD28 Co-stimulatory Receptor Modulator. *JAMA Surgery* 2014; Apr 16, 2014. Doi. 10.1001/jamasurg.2013.4841
116. Heine H, Louie A, Adamovicz J, Amemiva K, Fast R, Miller L, **Opal SM**, Palardy J, Parejo N, Sörgel F, Kinzig-Schippers M, Drusano G. Evaluation of imipenem for prophylaxis and treatment for *Yersinia pestis* delivered by aerosol in a mouse model of pneumonic plague. *Antimicrobial Agents and Chemotherapy* 2014; 58(6): 3276-3284.
117. DeLeon T, Chung HH, **Opal SM**, Dworkan J. Recurrent *Mycobacterium avium* complex empyema in a man with auto antibodies to interferon gamma. *Hawaiian Journal of Medicine and Public Health* 2014; 79: 15-17.
118. Cross A, Karreman HJ, Zhang L, Rosenberg R, **Opal SM**, Lees A. Immunization of cows with novel core glycolipid vaccine induces anti-endotoxin antibodies in bovine colostrum. *Vaccine* 2014; 32(46): 6107-6114.
119. Ramachandran G, Kaempfer R, Chung CS, Shivran A, Chahin AB, Palardy JE, Parejo N, Chen Y, Whitford M, Arad G, Hillman D, Shemesh R, Blackwelder W, Ayala A, Cross AS, **Opal SM**. CD 28 homodimer interface mimetic peptide as a novel inhibitor in experimental models of gram-negative sepsis. *Journal of Infectious Diseases* 2014; PMID 25305323
120. **Opal SM**, LaRosa SP. Recombinant human activated protein C as a therapy for severe sepsis: Lessons learned? *American Review of Respiratory and Critical Care Medicine* 2013;187(10): 1057-61.

121. Wittebole X, Laterre P-F, **Opal SM**. Targeting TLR4 intracellular domain to prevent ischemic liver disease: An innovative approach or just a futuristic dream? *Critical Care Medicine* 2014; 42(2):487-488.
122. **Opal SM**. The current understanding of sepsis and research priorities for the future: special focus issue of Virulence on sepsis. *Virulence* 2014; 5:1-3.
123. **Opal SM**. Dual inhibition of interleukin-1 beta and interleukin-18: A new treatment option for sepsis? *American Journal of Respiratory and Critical Care Medicine* 2014; 189(3): 242-244.
124. **Opal SM**, Fedson D. Immune dysfunction associated with influenza A H7N9: A potential target for treatment? Commentary *Critical Care* 2014; 18:135-137.
125. **Opal SM**. Number needed to treat-to get clinicians' attention. *Critical Care Medicine* 2014; 42 (11): 2444-2445.
126. **Opal SM**. Editorial comment-Sialic acid involved in hypermucoviscosity phenotype in *Klebsiella pneumoniae* and associated with resistance to neutrophil phagocytosis. *Virulence* 2014; 5(6): 648-649.
127. **Opal SM**, Pop-Vicas A. Molecular mechanisms of antibiotic resistance in bacteria. In: Principles and Practice of Infectious Diseases, 8th edition, JE Bennett, R Dolin and M Blaser (editors), 2014. Elsevier Publishers, Philadelphia, PA. p.235-251.
128. **Patrozou E., Fischer SA**. Cysticercosis. *Ferri's Clinical Advisor* 2014. Section One. In press.
129. **Pop-Vicas A, Opal SM**. The clinical impact of multidrug resistant gram-negative bacilli in the management of septic shock. *Virulence* 2014;5(1):1-7.
130. **Ramratnam B, Wing EJ**: Chapter 86. Host Defenses Against Infection. In Benjamin IJ, Griggs RC, Wing EJ, Fitz G (Eds). Andreoli and Carpenter's Cecil Essentials of Medicine. Elsevier, In., 2014. 9<sup>th</sup> edition. (in press)
131. Patel N, **Rana A**, Thomas A, Barnhart JC, **Flanigan TP, van den Berg JJ, Chan PA**. HIV Testing Practices among New England College Health Centers. *AIDS Research and Human Retroviruses* 2013;10(1):8.
132. Rahangdale L, Stewart A, Stewart R, Badell M, Levison J, Ellis P, Cohn S, Kempf M, Lazenby G, Tandont R, **Rana A**, Nguyen, Sturdevant M, Cohan D. Pregnancy Intentions among Women Living with HIV in the United States. *J Acquir Immune Defic Syndr*. 2014; 65(3):306-11. PMID:24525467 PMCID: PMC3927156
133. Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S: ING114915 Study

- Team. Once-daily Dolutegravir versus Darunavir plus Ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 Week results from the randomized open-label phase 3b study. *Lancet*. 2014 Jun 28; 383(9936):2222-31. Epub 2014 Apr 1. PMID: 24698485
134. Safren SA, Biello KB, Smeaton L, Mimiaga MJ, Walawander A, Lama JR, **Rana A**, Nyirenda M, Kayoyo VM, Samaneka W, Joglekar A, Celentano D, Martinez A, Remmert JE, Nair A, Lalloo UG, Kumarasamy N, Hakim J, Campbell TB: PEARLS (ACTG A5175) Study Team. Psychosocial Predictors of Non-adherence and Treatment failure in a large scale multi-national trial of Antiretroviral Therapy for HIV: Data from the ACTG A5175 / PEARLS Trial. *PLoS One*. 2014 Aug 25; 9(8):e104178. doi: 10.1371/journal.pone.0104178. eCollection 2014. PMID: 25153084
  135. Laws MB, Danielwicz M, **Rana A**, Kogelman L, Wilson IB. Health literacy in HIV treatment: accurate understanding of key biological treatment principles is not required for good ART adherence. *Aids and Behavior* 2014. In press.
  136. Fu JJ, Zaller ND, Yokell MA, Bazazi AR, **Rich JD**. Forced withdrawal from methadone maintenance therapy in criminal justice settings: a critical treatment barrier in the United States. *J Subst Abuse Treat* 44(5):502-5, 2013. PMCID: PMC3695471
  137. Zaller ND, McKenzie M, McGowan S, Green TC, **Rich JD**. Initiation of buprenorphine during incarceration and linkage to treatment upon release. *J Subst Abuse Treat* 45:222-26, 2013. PMCID: PMC3690138
  138. McNamara BC, Losikoff PT, Huguenin L, Macalino GE, **Rich JD**, Gregory SH. Increasing hepatitis C prevalence and associated risk behaviors among incarcerated young adults. *J Urban Health* [Epub ahead of print, May 31, 2013]. NIHMSID: 487365 (in process).
  139. Dumont DM, Gjelsvik A, Chen N, **Rich JD**. Hispanics, incarceration, and TB/HIV Screening: a missed opportunity for prevention. *J Immigrant Minority Health*, 15:711-17, 2013. PMCID: PMC3866805
  140. Green TC, Ray M, Bowman SE, McKenzie M, **Rich JD**. Two cases of intranasal naloxone self-administration in opioid overdose. *Subst Abuse* (in press), 2013. PMCID: PMC4019939
  141. Echenique IA, **Rich JD**. EFV/FTC/TDF-associated hepatotoxicity: a case report and review. *AIDS Pt Care STDs* 27(9):493-97, 2013. PMCID: PMC3760021
  142. Dumont DM, Gjelsvik A, Redmond N, **Rich JD**. Jails as public health partners: incarceration and disparities among medically underserved men. *Int'l J Men's Health* 12(3): 213-27, 2013. NIHMSID: 552673 (in process)
  143. **Rich JD**, Cortina SC, Cu-Uvin ZX, Dumont DM. Women, incarceration, and health. *Women's Health Issues* 23(6):e333-e334, 2013. (commentary) PMCID: PMC3935494

144. Ahalt C, Trestman RL, **Rich JD**, Greifinger RB, Williams BA. Paying the Price: The Pressing Need for Quality, Cost, and Outcomes Data to Improve Correctional Health Care for Older Prisoners. *J Am Geriatr Soc* 61(11):2013-19, 2013. PMID: PMC3984258
145. **Rich JD**, Chandler R, Williams BA, Dumont D, Wang EA, Taxman FS, Allen SA, Clarke JG, Greifinger RB, Wildeman C, Osher FC, Rosenberg S, Haney C, Mauser M, Western B. How health care reform can transform the health of criminal justice-involved individuals. *Health Aff* 33(3):462-67, 2014 PMID: PMC4034754
146. Patel K, Boutwell A, Brockmann B, **Rich JD**. Integrating correctional and community health care for formerly incarcerated persons eligible for Medicaid. *Health Aff* 33(3):468-73, 2014. PMID: PMC4028698
147. Rosen DL, Dumont D, Cislo AM, Brockmann BW, Traver A, **Rich JD**. Medicaid policies and practices in US State prison systems. *Am J Public Health* 104(3):418-20, 2014. PMID: PMC3953759
148. Larney S, Hado Sheryl, McKenzie M, **Rich JD**. Unknown quantities: HIV, viral Hepatitis, and sexually transmitted infections in Community Corrections. *Sex Transm Dis* 41(4):283, 2014 (letter to the editor) PMID: PMC4030420
149. **Rich JD**, Allen SA, Williams BA. Responding to hepatitis C through the criminal justice system. *New Engl J Med* 370(20):1871-4, 2014. (perspective) PMID: 24827032
150. Wakeman SE, Green TC, **Rich JD**. From documenting death to comprehensive care; applying lessons from the HIV/AIDS epidemic to addiction. *Am J Med* 127(6):465-6, 2014. (commentary) PMID: PMC4123318
151. Dumont DM, Allen SA, **Rich JD**. Sesame Street inspires physicians to advocate for criminal justice reform. *Ann Int Med* 161(7):522-23. PMID: 25285543
152. **Rich JD**. National Research Council and Institute of Medicine. Health and Incarceration: A Workshop Summary. Washington, DC: The National Academies Press, 2013. [http://www.nap.edu/catalog.php?record\\_id=18613](http://www.nap.edu/catalog.php?record_id=18613)
153. Dumont, Dora M., Kuester, Landon B., Rich, **Rich JD**. "Health Issues in Prisoner Reentry Models." In: *Encyclopedia of Criminology and Criminal Justice*, ed. Gerben Bruinsma, David Weisburd, New York: Springer Verlag. eScholarID:206573, 2014. (chapter contributor).
154. **Rich JD**. National Research Council. The Growth of Incarceration in the United States: Exploring Causes and Consequences. Washington, DC: The National Academies Press, 2014 (member, Committees on Causes and Consequences of High Rates of Incarceration). [http://www.nap.edu/catalog.php?record\\_id=18613](http://www.nap.edu/catalog.php?record_id=18613)

155. **Tang X**, Zheng D, Hu P, Zeng Z, **Li M**, Tucker L, Monahan R, Resnick MB, Liu M, **Ramratnam B**. Glycogen synthase kinase 3 beta inhibits microRNA-183-96-182 cluster via the  $\beta$ -Catenin/TCF/LEF-1 pathway in gastric cancer cells. *Nucleic Acids Res* 2014;42(5):2988-98.
156. Correia S, Cohen R, Gongvantana A, Ross S, Olchowski J, Devlin K, **Tashima K**, Navia B, Delamonte S. Relationship of plasma cytokines and clinical biomarkers to memory performance in HIV. (2013) *J Neuroimmunol.* 265(1-2):117-23. PMID: 24210837
157. Seider TR, Luo X, Gongvatana A, Devlin KN, de la Monte SM, Chasman JD, Yan P, **Tashima KT**, Navia B, Cohen RA. Verbal memory declines more rapidly with age in HIV infected versus uninfected adults. (2014) *J Clin Exp Neuropsychol.* March 19 [Epub ahead of print] PMID: 24645772
158. Caldwell JZ, Gongvatana A, Navia BA, Sweet LH, **Tashima KT**, Ding M, Cohen RA. Neural dysregulation during a working memory task in human immunodeficiency virus-seropositive and hepatitis C co-infected individuals. (2014) *J Neurovirol.* 20(4):398-411. Epub 2014 May 28. PMID: 24867610
159. Letendre SL, Mills AM, **Tashima KT**, Thomas DA, Min SS, Chen S, Song IH, Piscitelli SC; extended ING116080 study team. ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HI-1-Infected, Antiretroviral Therapy-Naive Subjects. *Clin Infect Dis.*2014 Oct1;59(7):1032-7. Doi: 10.1093/cid/ciu477. Epub 2014 Jun 18. PMID: 4944232 [PubMed – in process].
160. **Taylor LE**, Foont JA, DeLong AK, Wurcel A, Linas BP, Chapman S, Maynard MA, **Cu-Uvin S**, Mayer KH. The spectrum of undiagnosed hepatitis C virus infection in a US HIV clinic. *AIDS Patient Care STDS.* 2014; 28(1):4-9. PMID: 24428794 PMCID: PMC3894677
161. Merchant RC, Baird JR, Liu T, **Taylor LE**, **Montague BE**, Nirenberg TD. Brief intervention to Increase Emergency Department Uptake of Combined Rapid Human Immunodeficiency Virus and Hepatitis C Screening Among a Drug Misusing Population. *Academic Emergency Medicine.* 2014;21(7):752–767. PMID: 25125271.
162. Kinnard EN, **Taylor LE**, Galárraga O, Marshall BD. Estimating the true prevalence of hepatitis C in Rhode Island. *RI Med J.* 2014 ;97(7):19-24. PMID: 24983016.
163. Merchant RC, Baird JR, Liu T, **Taylor LE**. HCV among The Miriam Hospital and Rhode Island Hospital Adult ED Patients. *RI Med J.* 2014 1;97(7):35-9. PMID: 24983020.
164. **Taylor LE**. Hepatitis C virus infection: from margin to center in Rhode Island and beyond. *RI Med J.* 2014 Jul 1;97(7):15-8. PMID: 24983015.
165. **Taylor LE**. What price for a cure? *RI Med J.* 2014 ;97(7):16-7. PMID: 25184174.
166. Freiman JM, Huang W, White L, Geng EH, Hurt CB, **Taylor LE**, Overton ET, Cachay ER, Kitahata MM, Moore RD, Rodriguez B, Mayer KH, Linas BP. Current Practices of

- Screening for Incident Hepatitis C Virus Infection among HIV Infected, HCV Un-Infected Individuals in Primary Care. *Clin Infect Dis*. 2014 Sep 3. [Epub ahead of print] PMID: 25186591.
167. Venkatesan A, **Tunkel AR**, Bloch KC, Luring AS, Sejvar J, Bitnun A, Stahl JP, Mailles A, Drebot M, Rupprecht CE, Yoder J, Cope JR, Wilson MR, Whitley RJ, Sullivan J, Granerod J, Jones C, Eastwood K, Ward KN, Durrheim DN, Solbrig MV, Guo-Duong L, Glaser CA on behalf of the International Encephalitis Consortium. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the International Encephalitis Consortium. *Clin Infect Dis* 2013;57:1114-1128.
  168. **Tunkel AR**. Health disparities education – the time is now. *Rhode Island Med J* 2014;97(9):21.
  169. Brouwer MC, **Tunkel AR**, McKhann GM II, van de Beek D. Brain abscess. *N Engl J Med* 2014;371:447-456.
  170. **Tunkel AR**. Clinical features and diagnosis of acute bacterial meningitis in adults. In: UpToDate. Basow DS, ed. Waltham, MA. 2013.
  171. **Tunkel AR**. Initial therapy and prognosis of bacterial meningitis in adults. In: UpToDate. Basow DS, ed. Waltham, MA. 2013.
  172. Roos KL, **Tunkel AR**, van de Beek D, Scheld WM. Acute bacterial meningitis. In: *Infections of the Central Nervous System*, 4<sup>th</sup> ed. Scheld WM, Whitley RJ, Marra CM, eds. Philadelphia: Lippincott Williams & Wilkins. 2014:365-419.
  173. Klein M, Pfister HW, **Tunkel AR**, Scheld WM. Brain abscess. In: *Infections of the Central Nervous System*, 4<sup>th</sup> ed. Scheld WM, Whitley RJ, Marra CM, eds. Philadelphia: Lippincott Williams & Wilkins. 2014:522-549.
  174. Pfister HW, Klein M, **Tunkel AR**, Scheld WM. Epidural abscess. In: *Infections of the Central Nervous System*, 4<sup>th</sup> ed. Scheld WM, Whitley RJ, Marra CM, eds. Philadelphia: Lippincott Williams & Wilkins. 2014:550-565.
  175. **Tunkel AR**. Clinical features and diagnosis of acute bacterial meningitis in adults. In: UpToDate. Basow DS, ed. Waltham, MA. 2014.
  176. **Tunkel AR**. Treatment of bacterial meningitis caused by specific pathogens in adults. In: UpToDate. Basow DS, ed. Waltham, MA. 2014.
  177. **van den Berg JJ**, Rosen RK, Bregman DE, Thompson LA, Jensen KJ, Kiser PF, Katz DF, Buckheit K, Buckheit RW Jr, Morrow KM. “Set it and forget it”: Women's perceptions and opinions of long-acting topical vaginal gels. *AIDS Behav* 2014;18(5):862-70. doi: 10.1007/s10461-013-0652-4. PMID: PMC4018755.

178. **van den Berg JJ**, Bock B, Roberts MB, Stein LAR, Friedmann PD, Martin SA, Clarke JG. Cigarette smoking as an expression of independence and freedom among inmates in a tobacco-free prison in the United States. *Nicotine Tob Res* 2014;16(2):238-42. doi: 10.1093/ntr/ntt163. PMID: PMC3880237.
179. Morrow KM, Underhill K, **van den Berg JJ**, Vargas S, Rosen RK, Katz DF. User-identified gel characteristics: A qualitative exploration of perceived product efficacy of topical vaginal microbicides. *Arch Sex Behav* 2014 Jan 23. doi: 10.1007/s10508-013-0235-5. PMID: 24452632 (PMCID pending) [Epub ahead of print]
180. **van den Berg JJ**, Larson HE, Zimet GD, **Lally MA**. Bundling HPV vaccination and rapid HIV testing for young gay and bisexual men. *LGBT Health* 2014;1(3):233-237. doi:10.1089/lgbt.2014.0028. [Epub ahead of print]
181. Lantini R, **van den Berg JJ**, Roberts MB, Bock BC, Stein LAR, Parker DR, Friedmann PD, Clarke JG. Characteristics of smoking used cigarettes among an incarcerated population. *Psychol Addict Behav* 2014 Sep 1. PMID: 25180554 (PMCID pending) [Epub ahead of print]
182. Benjamin IJ, Griggs RC, **Wing EJ**, Fitz G (Eds). Andreoli and Carpenter's Cecil Essentials of Medicine. Elsevier, Inc., 2014. 9<sup>th</sup> edition. (in press)
183. **Wing EJ**: Infection of the Head and Neck. Chapter 91. In Benjamin IJ, Griggs RC, Wing EJ, Fitz G (Eds). Andreoli and Carpenter's Cecil Essentials of Medicine. Elsevier, Inc., 2014. 9<sup>th</sup> edition. (in press)
184. **Wing EJ**: Intra-Abdominal Abscess and Peritonitis. Chapter 95. In Benjamin IJ, Griggs RC, Wing EJ, Fitz G (Eds). Andreoli and Carpenter's Cecil Essentials of Medicine. Elsevier, Inc., 2014. 9<sup>th</sup> edition. (in press)
185. **Ziakas PD**, Karsaliakos P, Prodromou ML, **Mylonakis E**. Interleukin-6 polymorphisms and hematologic malignancy: a re-appraisal of evidence from genetic association studies. *Biomarkers* 2013;18(7):625-31. PMID: 24059848
186. **Ziakas PD**, Prodromou ML, Khoury JE, Zintzaras E, **Mylonakis E**. The Role of TLR4 896 A>G and 1196 C>T in Susceptibility to Infections: A Review and Meta-Analysis of Genetic Association Studies. *PLoS ONE* 2013;8(11):e81047. PMID: 24282567
187. Zacharioudakis IM, Zervou FN, **Ziakas PD**, **Mylonakis E**. Meta-Analysis of Methicillin Resistant Staphylococcus aureus Colonization and Risk of Infection in Dialysis Patients. *J Am Soc Nephrol* 2014;25(9):2131-41. PubMed PMID: 24652802
188. Zervou FN, Zacharioudakis IM, **Ziakas PD**, **Mylonakis E**. MRSA colonization and risk of infection in the neonatal and pediatric ICU: a meta-analysis. *Pediatrics* 2014 ;133(4):e1015-23. PMID: 24616358
189. **Ziakas PD**, Kourbeti I, **Mylonakis E**. Systemic Antifungal prophylaxis after hematopoietic stem cell transplantation: A meta-analysis. *Clin Ther* 2014;36(2):292-306.e1. PMID: 24439393

190. Arvanitis M, Anagnostou T, Kourkoumpetis TK, **Ziakas PD**, Desalermos A, **Mylonakis E**. The impact of antimicrobial resistance and aging in VAP outcomes: experience from a large tertiary care center. *PLoS One* 2014;9(2):e89984. doi: 10.1371/journal.pone.0089984. PubMed Central PMCID: PMC3937398
191. **Ziakas PD**, Anagnostou T, **Mylonakis E**. The prevalence and significance of MRSA colonization at admission in the general ICU setting: A meta-analysis of published studies. *Crit Care Med* 2014;42(2):433-44.
192. Kourbeti IS, **Ziakas PD**, **Mylonakis E**. Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. *Clin Infect Dis* 2014 Jun;58(12):1649-57. doi: 10.1093/cid/ciu185. Epub 2014 Mar 18. PubMed PMID: 24647016.
193. **Ziakas PD**, **Mylonakis E**. ACP Journal Club. Probiotics did not prevent antibiotic associated or *C. difficile* diarrhea in hospitalized older patients. *Ann Intern Med* 2014 ;160(12):JC6. doi: 10.7326/0003-4819-160-12-201406170-02006. PubMed PMID: 24935512.
194. Prodromou ML, **Ziakas PD**, Poulou LS, Karsaliakos P, Thanos L, **Mylonakis E**. FDG-PET is a robust tool for the diagnosis of spondylodiscitis: A meta-analysis of diagnostic data. *Clin Nucl Med* 2014;39(4):330-5.
195. Botsa E, Poulou LS, Koutsogiannis I, **Ziakas PD**, Koundouraki A, Alexopoulou E, Thanos L. CT-guided radiofrequency tumor ablation in children. *Pediatr Radiol* 2014 Jun 4. [Epub ahead of print] PubMed PMID: 24894971.
196. **Ziakas PD**, Pliakos EE, Zervou FN, **Knoll BM**, **Rice LB**, **Mylonakis E**. MRSA and VRE colonization in solid organ transplantation: a meta-analysis of published studies. *Am J Transplant* 2014 Aug;(8):1887-94. PubMed PMID: 25040438.
197. Zacharioudakis IM, **Ziakas PD**, **Mylonakis E**. *Clostridium difficile* infection in the hematopoietic unit: A meta-analysis of published studies. *Biol Blood Marrow Transplant* 2014;20(10):1650-4.
198. Zintzaras E, Miligkos M, **Ziakas P**, Balk EM, Mademtzoglou D, Doxani C, Mprotsis T, Gowri R, Xanthopoulou P, Mpoulimari I, Kokkali C, Dimoulou G, Rodopolou P, Stefanidis I, Kent DM, Hadjigeorgiou GM. Assessment of the Relative Effectiveness and Tolerability of Treatments of Type 2 Diabetes Mellitus: A Network Meta-analysis. *Clin Ther* 2014 Aug 7. pii: S0149-2918(14)00430-5. doi: 10.1016/j.clinthera.2014.06.035. [Epub ahead of print] Review. PubMed PMID: 25109773.
199. Zacharioudakis IM, Zervou FN, **Ziakas PD**, **Rice LB**, **Mylonakis E**. Vancomycin-Resistant Enterococci Colonization Among Dialysis Patients: A Meta-analysis of Prevalence, Risk Factors, and Significance. *Am J Kidney Dis* 2014 Jul 16. pii: S0272-6386(14)00907-X. doi: 10.1053/j.ajkd.2014.05.016. [Epub ahead of print] PubMed PMID: 25042816

200. Zacharioudakis IM, Zervou FN, Arvanitis M, **Ziakas PD**, **Mermel LA**, **Mylonakis E**. Antimicrobial Lock Solutions as a Method to Prevent Central Line-Associated Bloodstream Infections: A Meta-Analysis of Randomized Controlled Trials. *Clin Infect Dis* 2014 Aug 25. pii: ciu671. [Epub ahead of print] PubMed PMID: 25156111
201. Zacharioudakis IM, Zervou FN, **Ziakas PD**, **Mylonakis E**. Clostridium difficile infection: an undeniably common problem among hematopoietic transplant recipients. *Int J Hematol* 2014 Aug 20. [Epub ahead of print] PubMed PMID: 25139684.
202. Zervou FN, Zacharioudakis IM, **Ziakas PD**, **Rich JD**, **Mylonakis E**. Prevalence of and Risk Factors for Methicillin-Resistant Staphylococcus aureus Colonization in HIV Infection: A Meta-Analysis. *Clin Infect Dis* 2014 Jul 16. pii: ciu559. [Epub ahead of print] PubMed PMID: 25031291
203. Kourbeti IS, Vakis AF, **Ziakas PD**, Karabetsos D, Potolidis E, Christou S, Samonis G. Infections in patients undergoing craniotomy: risk factors associated with post-craniotomy meningitis. Clinical article. *J Neurosurg* [in press]
204. **Ziakas PD**, Zacharioudakis IM, Zervou FN, **Mylonakis E**. MRSA Prevention Strategies in the Intensive Care Unit: A clinical decision analysis. *Crit Care Med* [in press]
205. Arvanitis M, Zacharioudakis IM, Zervou F, **Ziakas PD**, **Fuchs B**, **Caliendo A**, **Mylonakis E**. Polymerase chain reaction in the diagnosis of invasive aspergillosis: A meta-analysis of diagnostic performance. *J Clin Microbiol* (in press).